In breast cancer, Bcl6 prevents mammary epithelial cell differentiation, induces epithelial mesenchymal transition (EMT), and it has been proposed as a molecular target for breast cancer therapy [6–8]. The gene discussed is BCL6; the disease is breast carcinoma.